Posted in:News Sandoz Enters IPR Battlefield on Humira® Patents By C. Nichole Gifford August 10, 2017 Comments are off Sandoz, Inc. (“Sandoz”) entered into the battlefield over patents related to AbbVie’s Humira® (adalimumab). On July 20, 2017,... Read more Tagged with: adalimumab, Humira®, Invalidity, IPR, News, PTAB, Sandoz, USPTO, Validity http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Coherus Files Four IPR Petitions on Humira® Patent By C. Nichole Gifford February 1, 2017 Comments are off Coherus Biosciences, Inc. (“Coherus”) has filed four petitions with the Patent Trial and Appeal Board (“PTAB”) for inter partes... Read more Tagged with: adalimumab, Amgen, Coherus, Humira®, Invalidity, IPR, Legal, News, PTAB, USPTO, Validity http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus